AbbVie on YouTube 

AbbVie is a North Chicago biopharmaceutical company that discovers, develops, and commercializes medicines rather than a pharmacy chain. On abbvie.com the listed Illinois firm writes about immunology, oncology, neuroscience, eye care, aesthetics, and other therapeutic areas, with a company figure of about fifty-seven thousand employees working on those franchises. That headcount is AbbVie’s own published yardstick, not an independent census and not a quality score. The 2013 Abbott spin-out still files as ABBV. Plant maps, pipeline tables, and indication lists belong on current labels and filings. The operating catalogue is prescription therapies and certain aesthetics products sold through licensed channels. Nothing in a Facebook film, an X thread, a LinkedIn post, or a YouTube cut is a diagnosis, a dosing instruction, or a reason to start, stop, or switch a medicine. Adverse events, pregnancy questions, and device-plus-drug combinations belong with a licensed clinician and with the pharmacovigilance routes AbbVie publishes. This is not medical advice. Official Facebook is AbbVieGlobal. Official X is abbvie. Official LinkedIn is abbvie. Official YouTube still uses the historic user/AbbVie path. They carry science stories, patient-inspired films, pipeline color, and hiring notes. They are not a sample closet, a prior-authorization desk, or a place to upload charts. Do not share medical records, insurance numbers, or login secrets in comments. Customers are physicians, health systems, researchers, and patients who must confirm every use against approved labeling. Media, medical-information, and investor mail belong on the contact routes AbbVie publishes. Follow the official pages for the ~57,000-person biopharma company, then verify every trial, indication, and site claim at the source. North Chicago remains the listed headquarters after the Abbott separation. Humira-era immunology still sits beside newer immunology, oncology, and neuroscience assets whose names belong on labels. Aesthetics brands are not a substitute for a licensed injector. Animal and eye-care stories, when AbbVie publishes them, still require a clinician. Patient-assistance and copay language, when it appears, is country-specific and means-tested; a Facebook comment cannot enroll anyone. Investigators should use published trial registries. Medical information units exist for licensed professionals; social community managers are not those units. Treat the fifty-seven-thousand figure as a company snapshot that will move at the next report. Follow labels, not influencers, for any product that requires a prescription.